Key result
Neurostimulation improves refractory angina symptoms, while EECP and gene therapy offer emerging or investigational benefit.
Why the study?
The multiplicity of therapeutic strategies for refractory angina indicates the failure of any single treatment option to provide consistent symptom control.
Answers are grounded in this paper and cite their sources.
Neurostimulation may aid refractory angina symptom control; leaves open EECP and gene therapy roles pending higher-level trials.
In summary, the number of therapeutic strategies for the treatment of refractory angina is an indication of the failure of any single option. Nevertheless, it is possible to improve symptom control for patients with this diagnosis. In particular, there is clear evidence for benefit from neurostimulation. EECP is a cumbersome technique, which shows promise despite being inappropriate for patients with severe heart failure or valvular disease. Gene therapy offers hope for the future, although cannot yet be recommended outside the setting of a clinical trial.
No takes yet. Share an insight, caveat, or question.
Faircloth et al. (2004) conducted a review in refractory angina. Neurostimulation, EECP, and Gene therapy was evaluated. Neurostimulation provides clear benefit for symptom control in refractory angina, while EECP shows promise and gene therapy remains investigational.
Synapse has enriched 10 related papers. Consider them for comparative context: